600+ sources. One page. See who else covered it.
European regulators on Thursday detailed their skepticism of data behind Amgen's rare disease drug Tavneos, explaining a decision last week to pull the drug from the market there. In new documents ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
The patient died in Bas-Uele's capital Buta after developing haemorrhagic Ebola-like symptoms.
'Childhood vaccination continues to be one of our most powerful tools to prevent illness and support child health in Canada,' the agency wrote.
'Childhood vaccination continues to be one of our most powerful tools to prevent illness and support child health in Canada,' the agency wrote.
A new report documenting California's rapidly growing silicosis epidemic among quartz countertop workers underscores the urgent need for a national effort focused on stronger surveillance, earlier…
A compound produced by bacteria in many people's digestive tracts increases the risk of developing Alzheimer's disease and speeds cognitive decline in dementia patients, making it a potential target…
About 26 months after failing two Phase 3 trials, an epilepsy treatment candidate is getting plucked off biopharma's shelves and will be given a new chance at life.